Tau Kinetics in Neurons and the Human Central Nervous System

Sato, Chihiro, Barthélemy, Nicolas R., Mawuenyega, Kwasi G., Patterson, Bruce W., Gordon, Brian A., Jockel-Balsarotti, Jennifer, Sullivan, Melissa, Crisp, Matthew J. +9 more·2018·Neuron

DOI 10.1016/j.neuron.2018.02.015

Cited by (584)

Items 101–200 of 584

Learnings about the complexity of extracellular tau aid development of a blood‐based screen for Alzheimer's disease
Zhicheng Chen, David Mengel, Ashvini Keshavan, Robert A. Rissman, Andrew Billinton, Michael S. Perkinton, Jennifer Percival‐Alwyn, Aaron P. Schultz, Michael J Properzi, Keith A. Johnson et al. · 2018 · Alzheimer s & Dementia
Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis
Kunal Dhiman, Kaj Blennow, Henrik Zetterberg, Ralph Nigel Martins, Veer Bala Gupta · 2019 · Cellular and Molecular Life Sciences
Tau as a Biomarker of Neurodegeneration
Sarah Holper, Rosie Watson, Nawaf Yassi · 2022 · International Journal of Molecular Sciences
Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
Zdeněk Fišar · 2022 · Biomolecules
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory
Franzmeier, Nicolai, Rubinski, Anna, Neitzel, Julia, Ewers, Michael, The Alzheimer’s Disease Neuroimaging Initiative (ADNI), Weiner, Michael W., Aisen, Paul, Petersen, Ronald, Jack, Clifford R., Jagust, William et al. · 2019 · Nature Communications
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease
Gai Ayalon, Seung-Hye Lee, Oskar Adolfsson, Corinne Foo‐Atkins, Jasvinder K. Atwal, Mira Blendstrup, Helen S. Booler, Joseph Bravo, Robert P. Brendza, Flávia Brunstein et al. · 2021 · Science Translational Medicine
Advances and considerations in AD tau-targeted immunotherapy
Alice Bittar, Nemil N. Bhatt, Rakez Kayed · 2019 · Neurobiology of Disease
Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: a contextualized review of the evidence
Gleason, Carey E., Zuelsdorff, Megan, Gooding, Diane C., Kind, Amy J. H., Johnson, Adrienne L., James, Taryn T., Lambrou, Nickolas H., Wyman, Mary F., Ketchum, Fred B., Gee, Alexander et al. · 2022 · Alzheimer's & Dementia
Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble TauIn Vivo
Tomáš Ondrejčák, Igor V. Klyubin, Grant T. Corbett, Graham Mathew Fraser, Wei Hong, Alexandra J. Mably, Matthew J. Gardener, Jayne Hammersley, Michael S. Perkinton, Andrew Billinton et al. · 2018 · Journal of Neuroscience
A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain
Ercan-Herbst, Ebru, Ehrig, Jens, Schöndorf, David C., Behrendt, Annika, Klaus, Bernd, Gomez Ramos, Borja, Prat Oriol, Nuria, Weber, Christian, Ehrnhoefer, Dagmar E. · 2019 · Acta Neuropathologica Communications
An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead
Joel Simrén, Nicholas James Ashton, Kaj Blennow, Henrik Zetterberg · 2019 · Current Opinion in Neurobiology
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease
Deborah O T Alawode, Amanda Heslegrave, Nicholas James Ashton, Thomas K. Karikari, Joel Simrén, Laia Montoliu‐Gaya, Josef Pannee, Antoinette O’Connor, Philip S.J. Weston, Juan Lantero‐Rodriguez et al. · 2021 · Journal of Internal Medicine
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Antoine Leuzy, Ariane Bollack, Daniela Pellegrino, Charlotte Elisabeth Teunissen, Renaud La Joie, Gil Dan Rabinovici, Nicolai Franzmeier, Keith A. Johnson, Frederik Barkhof, Leslie M. J. Shaw et al. · 2025 · Alzheimer s & Dementia
Current Status of Clinical Trials on Tau Immunotherapies
Ji, Changyi, Sigurdsson, Einar M. · 2021 · Drugs
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Kanta Horie, Nicolas R. Barthélemy, Salvatore Spina, Lawren A. VandeVrede, Yingxin He, Ross W. Paterson, Brenton A. Wright, Gregory Scott Day, Albert A. Davis, Celeste M M. Karch et al. · 2022 · Nature Medicine
Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer’s disease
Sebastian Niclas Roemer, Fabian Wagner, Lisa Evangelista, Boris‐Stephan Rauchmann, Amir Dehsarvi, Anna Steward, Anna Dewenter, Davina Biel, Zeyu Zhu, Julia Pescoller et al. · 2025 · Science Translational Medicine
Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies
Thomas Vogels, Antoine Leuzy, Claudia Cicognola, Nicholas James Ashton, Tomáš Smolek, Michal Novák, Kaj Blennow, Henrik Zetterberg, Tomáš Hromádka, Norbert Žilka et al. · 2019 · Biological Psychiatry
Specific post-translational modifications of soluble tau protein distinguishes Alzheimer’s disease and primary tauopathies
Nathalie Kyalu Ngoie Zola, Clémence Balty, Sébastien Pyr dit Ruys, Axelle Vanparys, Nicolas D. Huyghe, Gaëtan Herinckx, Manuel Johanns, Emilien Boyer, Pascal Kienlen‐Campard, Mark H. Rider et al. · 2023 · Nature Communications
Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
Zhou, Maotian, Haque, Rafi U., Dammer, Eric B., Duong, Duc M., Ping, Lingyan, Johnson, Erik C. B., Lah, James J., Levey, Allan I., Seyfried, Nicholas T. · 2020 · Clinical Proteomics
Tau immunotherapies: Lessons learned, current status and future considerations
Sandusky-Beltran, L.A., Sigurdsson, E.M. · 2020 · Neuropharmacology
Protein-protein interactions in neurodegenerative diseases: A conspiracy theory
T. Thompson, P. Chaggar, E. Kuhl, A. Goriely · 2020 · bioRxiv
Alzheimer’s disease – the journey of a healthy brain into organ failure
Todd Eliot Golde · 2022 · Molecular Neurodegeneration
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
Pieter Jelle Visser, Lianne Maria Reus, Johan Gobom, Iris E. Jansen, Ellen Dicks, Sven J. van der Lee, Magda Tsolaki, Frans R.J. Verhey, Julius Popp, Pablo Martínez‐Lage et al. · 2022 · Molecular Neurodegeneration
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Novak, Petr, Kontsekova, Eva, Zilka, Norbert, Novak, Michal · 2018 · Frontiers in Neuroscience
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
Lingzhi Ma, Lan Tan, Yanlin Bi, Xue‐Ning Shen, Wei Xu, Ya‐Hui Ma, Hong‐Qi Li, Qiang Dong, Jin‐Tai Yu · 2020 · Molecular Neurodegeneration
Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
M. Catarina Silva, Stephen J. Haggarty · 2019 · Annals of the New York Academy of Sciences
Mass spectrometry‐based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids
Magdalena Korecka, Leslie M. J. Shaw · 2021 · Journal of Neurochemistry
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Marta Milà‐Alomà, Marc Suárez‐Calvet, José Luís Molinuevo · 2019 · Therapeutic Advances in Neurological Disorders
Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming
Sun, Zhao, Kwon, Ji-Sun, Ren, Yudong, Chen, Shawei, Walker, Courtney K., Lu, Xinguo, Cates, Kitra, Karahan, Hande, Sviben, Sanja, Fitzpatrick, James A. J. et al. · 2024 · Science
Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease
Tohidul Islam, Emily Hill, Eric E. Abrahamson, Stijn Servaes, Denis S. Smirnov, Xuemei Zeng, Anuradha Sehrawat, Yijun Chen, Przemysław Radosław Kac, Hlin Kvartsberg et al. · 2025 · Nature Medicine
Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP
Jiang, Shan, Wen, Natalie, Li, Zeran, Dube, Umber, Del Aguila, Jorge, Budde, John, Martinez, Rita, Hsu, Simon, Fernandez, Maria V., Cairns, Nigel J. et al. · 2018 · Translational Psychiatry
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Jeffrey L. Cummings, Kaj Blennow, Keith A. Johnson, Michael B. Keeley, Randall John Bateman, José Luís Molinuevo, Jacques Touchon, Paul S. S. Aisen, Bruno J. Vellas · 2019 · The Journal of Prevention of Alzheimer s Disease
Ultrasensitive tau biosensor cells detect no seeding in Alzheimer’s disease CSF
Hitt, Brian D., Vaquer-Alicea, Jaime, Manon, Victor A., Beaver, Joshua D., Kashmer, Omar M., Garcia, Jan N., Diamond, Marc I. · 2021 · Acta Neuropathologica Communications
No association of salivary total tau concentration with Alzheimer's disease
Nicholas James Ashton, Mark Ide, Michael Schöll, Kaj Blennow, Simon Lovestone, Abdul Hye, Henrik Zetterberg · 2018 · Neurobiology of Aging
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Antoine Leuzy, Nicholas James Ashton, Niklas Mattsson, Alessandra Dodich, Marina Boccardi, Julie Corre, Alexander E. Drzezga, Agneta K. Nordberg, Rik Ossenkoppele, Henrik Zetterberg et al. · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
Protein lifetimes in aged brains reveal a proteostatic adaptation linking physiological aging to neurodegeneration
Verena Kluever, Belisa Russo, Sunit Mandad, Nisha Hemandhar Kumar, Mihai Alevra, Alessandro Ori‬‬, Silvio O. Rizzoli, Henning Urlaub, Anja Schneider, Eugenio F. Fornasiero · 2022 · Science Advances
Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use
Cristina d’Abramo, Luciano D'adamio, Luca Giliberto · 2020 · Journal of Personalized Medicine
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease
Nicolai Franzmeier, Sebastian Niclas Roemer, Alexander Maximilian Bernhardt, Amir Dehsarvi, Anna Dewenter, Anna Steward, Davina Biel, Lukas K. Frontzkowski, Zeyu Zhu, Johannes S. Gnörich et al. · 2025 · Molecular Neurodegeneration
Tau immunotherapies for Alzheimer’s disease
Justin L. Hoskin, Marwan Noel Sabbagh, Yazan M. Al-Hasan, Boris Decourt · 2019 · Expert Opinion on Investigational Drugs
A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease
Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Yorghos Tripodis, Ann Carolyn McKee, Thor D. Stein, Brett M. Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin et al. · 2020 · Neurobiology of Aging
Targeting aging and age-related diseases with vaccines
Wu, Ruochen, Sun, Fei, Zhang, Weiqi, Ren, Jie, Liu, Guang-Hui · 2024 · Nature Aging
Passive immunotherapy for Alzheimer's disease
Xiaoyi Guo, Yan Li, Denghong Zhang, Yingjun Zhao · 2024 · Ageing Research Reviews
Recapitulation of Endogenous 4R Tau Expression and Formation of Insoluble Tau in Directly Reprogrammed Human Neurons
Capano, Lucia S., Sato, Chihiro, Ficulle, Elena, Yu, Anan, Horie, Kanta, Kwon, Ji-Sun, Burbach, Kyle F., Barthélemy, Nicolas R., Fox, Susan G., Karch, Celeste M. et al. · 2022 · Cell Stem Cell
Characterization of tau binding by gosuranemab
Richelle Sopko, Olga Golonzhka, Joseph W. Arndt, Chao Quan, Julie Czerkowicz, Andrew Cameron, Benjamin Smith, Murugesan Yogapriya, Garrett S. Gibbons, Soojung Kim et al. · 2020 · Neurobiology of Disease
The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?
Yann Fichou, Youssra K. Al‐Hilaly, François Devred, Caroline Smet‐Nocca, Philipp O. Tsvetkov, Joke Verelst, Joris Winderickx, Nick Geukens, Eugeen Vanmechelen, Audrey Perrotin et al. · 2019 · Acta Neuropathologica Communications
Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer’s Therapeutics
Varnavas D. Mouchlis, Georgia Melagraki, Lefteris C. Zacharia, Antreas Afantitis · 2020 · International Journal of Molecular Sciences
Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
Dai, Jingting, Johnson, Erik C. B., Dammer, Eric B., Duong, Duc M., Gearing, Marla, Lah, James J., Levey, Allan I., Wingo, Thomas S., Seyfried, Nicholas T. · 2018 · Frontiers in Molecular Neuroscience
Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain
Kanta Horie, Nicolas R. Barthélemy, Nipun Mallipeddi, Yan Li, Erin E. Franklin, Richard J. Perrin, Randall John Bateman, Chihiro Sato · 2020 · Acta Neuropathologica Communications
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Gallen Triana‐Baltzer, Setareh Moughadam, Randy Slemmon, Kristof Van Kolen, Clara Theunis, Marc H. Mercken, Hartmuth Christian Kolb · 2021 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Physiology of Glymphatic Solute Transport and Waste Clearance from the Brain
Lucy Zhao, Allen Tannenbaum, Erik N.T.P. Bakker, Helene Benveniste · 2022 · Physiology
Elevated CSF GAP-43 is associated with accelerated tau accumulation and spread in Alzheimer’s disease
Nicolai Franzmeier, Amir Dehsarvi, Anna Steward, Davina Biel, Anna Dewenter, Sebastian Niclas Roemer, Fabian Wagner, Mattes Groß, Matthias Brendel, Alexis Moscoso et al. · 2024 · Nature Communications
Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report
Randall John Bateman, Kaj Blennow, Rachelle Smith Doody, Suzanne B. Hendrix, Simon Lovestone, Stephen Salloway, Rachel J. Schindler, Michael Walter Weiner, Henrik Zetterberg, Paul S. S. Aisen et al. · 2019 · The Journal of Prevention of Alzheimer s Disease
Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Iqbal, Iram, Saqib, Fatima, Mubarak, Zobia, Latif, Muhammad Farhaj, Wahid, Muqeet, Nasir, Bushra, Shahzad, Hamna, Sharifi-Rad, Javad, Mubarak, Mohammad S. · 2024 · European Journal of Medical Research
Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals
Chhatwal, Jasmeer P., Schultz, Aaron P., Dang, Yifan, Ostaszewski, Beth, Liu, Lei, Yang, Hyun-Sik, Johnson, Keith A., Sperling, Reisa A., Selkoe, Dennis J. · 2020 · Nature Communications
Fluid biomarkers in Alzheimer's disease
Simrén, Joel, Elmgren, Anders, Blennow, Kaj, Zetterberg, Henrik · 2023 · Advances in Clinical Chemistry
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
Melissa Erin Murray, Christina M. Moloney, Naomi Kouri, Jeremy A. Syrjanen, Billie J. Matchett, Darren M. Rothberg, Jessica F. Tranovich, Tiffany N. Hicks Sirmans, Heather J. Wiste, Baayla D.C. Boon et al. · 2022 · Molecular Neurodegeneration
KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease
Neitzel, Julia, Franzmeier, Nicolai, Rubinski, Anna, Dichgans, Martin, Brendel, Matthias, Alzheimer’s Disease Neuroimaging Initiative (ADNI), Weiner, Michael, Aisen, Paul, Petersen, Ronald, Jack, Clifford R. et al. · 2021 · Nature Communications
The AD tau core spontaneously self-assembles and recruits full-length tau to filaments
Yari Carlomagno, Sireesha Manne, Michael A. Deture, Mercedes Prudencio, Yong‐Jie Zhang, Rana Hanna Al‐Shaikh, Judith A. Dunmore, Lillian M. Daughrity, Yuping Song, Monica Castanedes‐Casey et al. · 2021 · Cell Reports
Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature
Henrik Zetterberg · 2022 · Alzheimer s & Dementia
SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases
Ross W. Paterson, Audrey Gabelle, Brendan P. Lucey, Nicolas R. Barthélemy, Claire Alexandra Leckey, Christophe Hirtz, Sylvain Lehmann, Chihiro Sato, Bruce W. Patterson, Tim West et al. · 2019 · Nature Reviews Neurology
Biomarkers of Alzheimer Disease
Melissa M. Budelier, Randall John Bateman · 2019 · The Journal of Applied Laboratory Medicine
Advancing combination therapy for Alzheimer's disease
S. Salloway, Jeff Sevingy, K. Budur, Jan Pederson, R. DeMattos, P. von Rosenstiel, A. Páez, R. Evans, Christopher J. Weber, James A. Hendrix et al. · 2020 · Alzheimer's & Dementia
Elucidating Tau function and dysfunction in the era of cryo-EM
Guy M. Lippens, Benoı̂t Gigant · 2019 · Journal of Biological Chemistry
CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
Kristi Henjum, Else Quist‐Paulsen, Henrik Zetterberg, Kaj Blennow, Lars N. G. Nilsson, Leiv Otto Watne · 2018 · Journal of Neuroinflammation
Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment
Sophia Schedin‐Weiss, Stefan Gaunitz, Ping Sui, Qiushi Chen, Stuart M. Haslam, Kaj Blennow, Bengt G. Winblad, Anne Dell, Lars O. Tjernberg · 2019 · FEBS Journal
The Use of Antimicrobial and Antiviral Drugs in Alzheimer’s Disease
Umar Iqbal, Emma Zeng, Giulio Maria Pasinetti · 2020 · International Journal of Molecular Sciences
Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies
Ivan Kmezic, Kristin Samuelsson, Anja Finn, Zane Upate, Kaj Blennow, Henrik Zetterberg, Rayomand Press · 2022 · European Journal of Neurology
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
Jozef Hanes, Andrej Kováč, Hlin Kvartsberg, Eva Kontseková, Ľubica Fialová, Stanislav Katina, Branislav Kováčech, Eva Stevens, Jakub Hort, Martin Vyhnálek et al. · 2020 · Neurology
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Juan Lantero‐Rodriguez, Anniina Snellman, Andréa Lessa Benedet, Marta Milà‐Alomà, Elena Camporesi, Laia Montoliu‐Gaya, Nicholas James Ashton, Agathe Vrillon, Thomas K. Karikari, Juan Domingo Gispert et al. · 2021 · EMBO Molecular Medicine
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
Anniina Snellman, Juan Lantero‐Rodriguez, Andreja Emeršič, Agathe Vrillon, Thomas K. Karikari, Nicholas James Ashton, Milica Gregorič Kramberger, Saša Čučnik, Claire Paquet, Uroš Rot et al. · 2021 · Brain
A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease
Melissa M. Budelier, Yingxin He, Nicolas R. Barthélemy, Hong Jiang, Yan Li, Ethan Park, Rachel L. Henson, Suzanne E. Schindler, David M. Holtzman, Randall John Bateman · 2022 · Brain Communications
A combinatorial native MS and LC-MS/MS approach reveals high intrinsic phosphorylation of human Tau but minimal levels of other key modifications
Friedel Drepper, Jacek Biernat, Senthilvelrajan Kaniyappan, Helmut E. Meyer, Eva‐Maria Mandelkow, Bettina Warscheid, Eckhard Mandelkow� · 2020 · Journal of Biological Chemistry
Large‐scale deep proteomic analysis in Alzheimer's disease brain regions across race and ethnicity
Seifar, Fatemeh, Fox, Edward J., Shantaraman, Anantharaman, Liu, Yue, Dammer, Eric B., Modeste, Erica, Duong, Duc M., Yin, Luming, Trautwig, Adam N., Guo, Qi et al. · 2024 · Alzheimer's & Dementia
Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression
Chen, Hsu-Hsin, Liu, Peter, Auger, Paul, Lee, Seung-Hye, Adolfsson, Oskar, Rey-Bellet, Lorianne, Lafrance-Vanasse, Julien, Friedman, Brad A., Pihlgren, Maria, Muhs, Andreas et al. · 2018 · Scientific Reports
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg
Pawel Obrocki, Ayesha Khatun, Deborah Ness, Konstantin A. Senkevich, Jörg Hanrieder, Federica Capraro, Niklas Mattsson, Ulf Andréasson, Erik Portelius, Nicholas James Ashton et al. · 2020 · Alzheimer s Research & Therapy
Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals
Pâmela C.L. Ferreira, Joseph Therriault, Cécile Tissot, João Pedro Ferrari‐Souza, Andréa Lessa Benedet, Guilherme Povala, Bruna Bellaver, Douglas Teixeira Leffa, Wagner Scheeren Brum, Firoza Zubeida Lussier et al. · 2023 · Alzheimer s & Dementia
Regulatory mechanisms for the axonal localization of tau protein in neurons
Iwata, Minori, Watanabe, Shoji, Yamane, Ayaka, Miyasaka, Tomohiro, Misonou, Hiroaki · 2019 · Molecular Biology of the Cell
Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy
M. Catarina Silva, Ghata Nandi, Katherine A. Donovan, Quan Cai, Bethany C. Berry, Radosław P. Nowak, Eric S. Fischer, Nathanael S. Gray, Fleur M. Ferguson, Stephen J. Haggarty · 2022 · Frontiers in Cellular Neuroscience
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Jean‐Philippe Courade, Henrik Zetterberg, Günter U. Höglinger, Ilse Dewachter · 2025 · Cell
MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy
Jennifer Louise Whitwell, Nirubol Tosakulwong, Christopher G. Schwarz, Hugo Botha, Matthew L. Senjem, Anthony J. Spychalla, J. Eric Ahlskog, David S. Knopman, Ronald Carl Petersen, Clifford R. Jack et al. · 2018 · Movement Disorders
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
Pontus Erickson, Joel Simrén, Wagner Scheeren Brum, Gilda E. Ennis, Gwendlyn Kollmorgen, Ivonne Suridjan, Rebecca E. Langhough, Erin McMullen Jonaitis, Carol Ann Van Hulle, Tobey J. Betthauser et al. · 2023 · JAMA Neurology
Turnover atlas of proteome and phosphoproteome across mouse tissues and brain regions
Wenxue Li, Abhijit Dasgupta, Ka Yang, Shisheng Wang, Nisha Hemandhar Kumar, Surendhar Reddy Chepyala, Jay M. Yarbro, Zhenyi Hu, Barbora Šalovská, Eugenio F. Fornasiero et al. · 2025 · Cell
Soluble tau aggregates inhibit synaptic long-term depression and amyloid β-facilitated LTD in vivo
Tomáš Ondrejčák, Neng‐Wei Hu, Yingjie Qi, Igor V. Klyubin, Grant T. Corbett, Graham Mathew Fraser, Michael S. Perkinton, Dominic M. Walsh, Andrew Billinton, Michael J. Rowan · 2019 · Neurobiology of Disease
Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings
Kaj Blennow, Henrik Zetterberg · 2019 · Progress in molecular biology and translational science
Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease
Sivaprakasam R. Saroja, Abhijeet Sharma, Patrick R. Hof, Ana C. Pereira · 2021 · Alzheimer s & Dementia
Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
Antoine Leuzy, Claudia Cicognola, Konstantinos Chiotis, Laure Saint‐Aubert, Laëtitia Lemoine, Niels Andreasen, Henrik Zetterberg, Keqiang Ye, Kaj Blennow, Kina Höglund et al. · 2019 · European Journal of Nuclear Medicine and Molecular Imaging
Monitoring phagocytic uptake of amyloid β into glial cell lysosomes in real time
Prakash, Priya, Jethava, Krupal P., Korte, Nils, Izquierdo, Pablo, Favuzzi, Emilia, Rose, Indigo V. L., Guttenplan, Kevin A., Manchanda, Palak, Dutta, Sayan, Rochet, Jean-Christophe et al. · 2021 · Chemical Science
Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction
Lubov A. Ezerskiy, Kathleen M. Schoch, Chihiro Sato, Mariana Beltcheva, Kanta Horie, Frank Rigo, Ryan Martynowicz, Celeste M M. Karch, Randall John Bateman, Timothy M. Miller · 2021 · JCI Insight
Tau and other proteins found in Alzheimer’s disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans
Sabrina Simoes, Jessica L. Neufeld, Gallen Triana‐Baltzer, Setareh Moughadam, Emily I. Chen, Milankumar Kothiya, Yasir H. Qureshi, Vivek M. Patel, Lawrence S. Honig, Hartmuth Christian Kolb et al. · 2020 · Science Translational Medicine
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease
Eunice Eun Seo Chang, Philip Wing‐Lok Ho, Huifang Liu, Shirley Yin-Yu Pang, Chi-Ting Leung, Yasine Malki, Zoe Yuen-Kiu Choi, David Boyer Ramsden, Shu‐Leong Ho · 2022 · Translational Neurodegeneration
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
Emma E. Wolters, Rik Ossenkoppele, Sander C.J. Verfaillie, Emma M. Coomans, Tessa Timmers, Denise Visser, Hayel Tuncel, Sandeep S.V. Golla, Albert D. Windhorst, Ronald Boellaard et al. · 2020 · European Journal of Nuclear Medicine and Molecular Imaging
Biomarker potential of brain‐secreted extracellular vesicles in blood in Alzheimer's disease
Badhwar, AmanPreet, Haqqani, Arsalan S. · 2020 · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies
Élodie Leroux, Romain Perbet, R. Caillierez, K. Richetin, Sarah Lieger, Jeanne Espourteille, Thomas Bouillet, S. Bégard, Clément Danis, A. Loyens et al. · 2021 · Molecular Therapy
Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications
Rita Azevedo, Chloé Jacquemin, Nicolas Villain, François Fenaille, Foudil Lamari, François Bécher · 2022 · Cells
Structure‐Based Discovery of A Small Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) that Significantly Reduces Alzheimer's Disease Neuropathology
Prasenjit Mondal, Ping Bai, Ashley Gomm, Grisilda Bakiasi, Chih‐Chung Lin, Yongle Wang, Se Hoon Choi, Rudolph E. Tanzi, Changning Wang, Can Martin Zhang · 2023 · Advanced Science
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Juan Lantero‐Rodriguez, Gemma Salvadó, Anniina Snellman, Laia Montoliu‐Gaya, Wagner Scheeren Brum, Andréa Lessa Benedet, Niklas Mattsson, Pontus Tideman, Shorena Janelidze, Sebastian Palmqvist et al. · 2024 · Molecular Neurodegeneration
Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease
Maarten Timmers, Ina C. Tesseur, Jennifer Bogert, Henrik Zetterberg, Kaj Blennow, Anne Börjesson‐Hanson, Miquel Baquero, Merçé Boada, CHRISTOPHER C. RANDOLPH, Luc Tritsmans et al. · 2019 · Neurobiology of Aging
N-terminal tau truncation in the pathogenesis of Alzheimer's disease (AD): Developing a novel diagnostic and therapeutic approach
Giuseppina Amadoro, Valentina Latina, Veronica Corsetti, Pietro Calissano · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes
Marshall S. Goodwin, Olga Sinyavskaya, Franklin Burg, Veronica O’Neal, Carolina Ceballos‐Diaz, Pedro E. Cruz, Jada M. Lewis, Benoit I. Giasson, Peter Davies, Todd Eliot Golde et al. · 2020 · Molecular Therapy
Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
Eleonora M. Vromen, Sterre C.M. de Boer, Charlotte Elisabeth Teunissen, Annemieke J.M. Rozemüller, Anne Sieben, Maria Bjerke, Alzheimer’s Disease Neuroimaging Initiative, Pieter Jelle Visser, Femke H. Bouwman, Sebastiaan Engelborghs et al. · 2022 · Brain